Saba Capital Management, L.P. 13D and 13G filings for Tekla Life Sciences Investors:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-01 9:49 pm Sale |
2025-03-31 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 3,188,405 11.360% |
-132,263 (-3.98%) |
Filing |
| 2024-06-03 09:15 am Purchase |
2024-05-30 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 3,320,668 12.390% |
295,066 (+9.75%) |
Filing |
| 2024-04-29 10:52 am Purchase |
2024-04-25 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 3,025,602 11.290% |
412,829 (+15.80%) |
Filing |
| 2024-04-17 08:32 am Purchase |
2024-04-15 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 2,612,773 9.750% |
398,699 (+18.01%) |
Filing |
| 2024-02-07 07:55 am Purchase |
2024-02-05 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 2,214,074 8.260% |
457,547 (+26.05%) |
Filing |
| 2024-01-12 11:41 am Purchase |
2024-01-10 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 1,756,527 6.560% |
335,227 (+23.59%) |
Filing |
| 2023-12-29 07:54 am Purchase |
2023-12-20 | 13D | Tekla Life Sciences Investors HQL |
Saba Capital Management, L.P. | 1,421,300 5.310% |
1,421,300 (New Position) |
Filing |